Once the bioactive component has been obtained in pure
form, either as a novel structure or as a known compound exhibiting previously unreported activity, it must then betested in a series of biological assays to determine its efficacy,potency, toxicity, and pharmacokinetics. These assays will help to determine the priority of the compound’s spectrum of activity within the portfolio of compounds that a group may be assessing for advanced development as either drug candidates or leads thereto.